BR112022022341A2 - Compostos heterocíclicos como receptor desencadeador expresso em agonistas de células mieloides 2 e métodos de uso - Google Patents

Compostos heterocíclicos como receptor desencadeador expresso em agonistas de células mieloides 2 e métodos de uso

Info

Publication number
BR112022022341A2
BR112022022341A2 BR112022022341A BR112022022341A BR112022022341A2 BR 112022022341 A2 BR112022022341 A2 BR 112022022341A2 BR 112022022341 A BR112022022341 A BR 112022022341A BR 112022022341 A BR112022022341 A BR 112022022341A BR 112022022341 A2 BR112022022341 A2 BR 112022022341A2
Authority
BR
Brazil
Prior art keywords
myeloid
compounds
methods
heterocyclic compounds
receptor trigger
Prior art date
Application number
BR112022022341A
Other languages
English (en)
Inventor
C Czabaniuk Lara
Hopper Timothy
Houze Jonathan
Panteleev Jane
Rescourio Gwenaella
Santora Vincent
Wang Haoxuan
D White Ryan
R Wong Alice
Wu Yongwei
Bos Maxence
Mancuso John
Franzoni Ivan
Original Assignee
Amgen Inc
Vigil Neuroscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc, Vigil Neuroscience Inc filed Critical Amgen Inc
Publication of BR112022022341A2 publication Critical patent/BR112022022341A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems

Abstract

COMPOSTOS HETEROCÍCLICOS COMO RECEPTOR DESENCADEADOR EXPRESSO EM AGONISTAS DE CÉLULAS MIELOIDES 2 E MÉTODOS DE USO. A presente invenção refere-se a compostos da Fórmula I, úteis para a ativação de Receptor Desencadeador Expresso em Células Mieloides 2 (TREM2). A presente invenção também se refere a composições farmacêuticas que compreendem os compostos, usos dos compostos e composições para tratamento de, por exemplo, um distúrbio neurodegenerativo. Além disso, a presente invenção refere-se a intermediários úteis na síntese de compostos da Fórmula I.
BR112022022341A 2020-05-04 2021-05-04 Compostos heterocíclicos como receptor desencadeador expresso em agonistas de células mieloides 2 e métodos de uso BR112022022341A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063019772P 2020-05-04 2020-05-04
PCT/US2021/070507 WO2021226629A1 (en) 2020-05-04 2021-05-04 Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use

Publications (1)

Publication Number Publication Date
BR112022022341A2 true BR112022022341A2 (pt) 2023-01-10

Family

ID=78468522

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022022341A BR112022022341A2 (pt) 2020-05-04 2021-05-04 Compostos heterocíclicos como receptor desencadeador expresso em agonistas de células mieloides 2 e métodos de uso

Country Status (19)

Country Link
US (3) US11608344B2 (pt)
EP (1) EP4146222A1 (pt)
JP (1) JP2023525035A (pt)
KR (1) KR20230019822A (pt)
CN (1) CN115867284A (pt)
AR (1) AR122010A1 (pt)
AU (1) AU2021266805A1 (pt)
BR (1) BR112022022341A2 (pt)
CA (1) CA3182105A1 (pt)
CL (1) CL2022003047A1 (pt)
CO (1) CO2022015930A2 (pt)
CR (1) CR20220560A (pt)
CU (1) CU20220064A7 (pt)
EC (1) ECSP22089527A (pt)
IL (1) IL297833A (pt)
MX (1) MX2022013842A (pt)
PE (1) PE20230846A1 (pt)
TW (1) TW202208355A (pt)
WO (1) WO2021226629A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202208355A (zh) 2020-05-04 2022-03-01 美商安進公司 作為骨髓細胞觸發受體2促效劑之雜環化合物及使用方法
CN116322696A (zh) 2020-05-04 2023-06-23 安进公司 作为髓样细胞上表达的触发受体2激动剂的杂环化合物和使用方法
WO2022120390A1 (en) * 2020-12-04 2022-06-09 Vigil Neuroscience, Inc. Treatment of diseases related to atp-binding cassette transporter 1 dysfunction using trem2 agonists
IL308167A (en) * 2021-05-04 2023-12-01 Vigil Neuroscience Inc Heterocyclic compounds as agonists for an excitatory receptor expressed on myeloid cells 2 and methods of use
WO2023192288A1 (en) * 2022-03-28 2023-10-05 Denali Therapeutics Inc. Monovalent anti-trem2 binding molecules and methods of use thereof

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2940972A (en) 1957-06-27 1960-06-14 Thomae Gmbh Dr K Tri-and tetra-substituted pteridine derivatives
US2963481A (en) 1959-11-27 1960-12-06 Smith Kline French Lab 6-pteridinecarboxylic acid esters
IL112235A (en) 1994-01-03 2000-06-29 Acea Pharm Inc 1,4-dihydro-pyrido¬2,3-b¾pyrazine-2,3-dione (5 or 8) oxide derivatives and pharmaceutical compositions containing them
AU9503998A (en) 1997-10-28 1999-05-17 Warner-Lambert Company Novel 7-substituted quinazolin-2,4-diones useful as antibacterial agents
EP1345603A4 (en) 2000-12-20 2004-09-08 Merck & Co Inc P38 KINASE INHIBITORS (HALO-BENZO CARBONYL) HETEROCYCLO- FUSIONNES PHENYL
JP2003005355A (ja) 2001-06-20 2003-01-08 Fuji Photo Film Co Ltd 電子線又はｘ線用ネガ型レジスト組成物
WO2005007099A2 (en) 2003-07-10 2005-01-27 Imclone Systems Incorporated Pkb inhibitors as anti-tumor agents
AU2004283479A1 (en) 2003-10-17 2005-05-06 4 Aza Bioscience Nv Heterocycle-substituted pteridine derivatives and their use in therapy
BRPI0415683A (pt) 2003-11-03 2006-12-19 Warner Lambert Co inibidores da reabsorção de norepinefrina para o tratamento de distúrbios do sistema nervoso central
CA2563038C (en) 2004-04-02 2013-10-29 Gaik Beng Kok Neurologically-active compounds
US20070054916A1 (en) 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
US20070032493A1 (en) 2005-05-26 2007-02-08 Synta Pharmaceuticals Corp. Method for treating B cell regulated autoimmune disorders
WO2006128129A2 (en) 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating cancer
KR100659088B1 (ko) 2005-07-15 2006-12-21 삼성에스디아이 주식회사 디플루오로피리딘계 화합물 및 이를 이용한 유기 발광 소자
US20080261974A1 (en) 2005-09-23 2008-10-23 Kevin J Duffy Novel Chemical Compounds
JP2009528387A (ja) 2006-03-02 2009-08-06 スミスクライン・ビーチャム・コーポレイション Ｐｉ３キナーゼ阻害剤として用いるためのチアゾロン
US7855194B2 (en) * 2006-03-27 2010-12-21 Hoffmann-La Roche Inc. Pyrimidine, quinazoline, pteridine and triazine derivatives
US20090318456A1 (en) 2006-07-06 2009-12-24 Gilead Sciences, Inc. Substituted pteridines for the treatment and prevention of viral infections
US7635683B2 (en) 2006-08-04 2009-12-22 Enanta Pharmaceuticals, Inc. Quinoxalinyl tripeptide hepatitis C virus inhibitors
LT2057156T (lt) 2006-08-23 2017-05-25 Kudos Pharmaceuticals Limited 2-metilmorfolino pirido-, pirazo- ir pirimidopirimidino dariniai kaip mtor slopikliai
AU2008241483B2 (en) 2007-04-18 2011-03-24 Amgen Inc. Quinolones and azaquinolones that inhibit prolyl hydroxylase
EP2217234A2 (en) 2007-10-15 2010-08-18 AstraZeneca AB Combinations of mek inhibitors with mtor inhibitors
US20110098267A1 (en) 2008-02-07 2011-04-28 Synta Pharmaceuticals Corporation Topical formulations for the treatment of psoriasis
US8298825B1 (en) 2008-08-25 2012-10-30 The General Hospital Corporation TGF-beta receptor inhibitors to enhance direct reprogramming
US20120021519A1 (en) 2008-09-19 2012-01-26 Presidents And Fellows Of Harvard College Efficient induction of pluripotent stem cells using small molecule compounds
EP2356109B1 (en) 2008-10-10 2016-12-07 VM Discovery, Inc. Compositions and methods for treating alcohol use disorders, pain and other diseases
EP2408744A1 (en) 2009-03-18 2012-01-25 Schering Corporation Bicyclic compounds as inhibitors of diacylglycerol acyltransferase
US8691187B2 (en) 2009-03-23 2014-04-08 Eli Lilly And Company Imaging agents for detecting neurological disorders
WO2011014039A1 (en) 2009-07-31 2011-02-03 Rohm And Haas Electronic Materials Korea Ltd. Novel organic electroluminescent compounds and organic electroluminescent device using the same
US20110124597A1 (en) 2009-09-25 2011-05-26 Anacor Pharmaceuticals, Inc. Boron containing small molecules
BR112012022868A2 (pt) * 2010-03-16 2018-06-05 Merck Patent Gmbh morfolinilquinazolinas
US9139592B2 (en) 2010-06-14 2015-09-22 Trt Pharma Inc. Modulators of Nrf2 and uses thereof
CN102887895B (zh) 2011-07-22 2016-08-24 山东轩竹医药科技有限公司 吡啶并嘧啶类mTOR抑制剂
KR101497124B1 (ko) 2011-11-28 2015-03-06 덕산네오룩스 주식회사 유기전기소자용 화합물, 이를 포함하는 유기전기소자 및 그 전자 장치
BR112014019699B1 (pt) 2012-02-08 2021-12-07 Janssen Sciences Ireland Uc Derivados de piperidino-pirimidina, seu uso no tratamento de infecções virais e composição farmacêutica que os compreende
CN103374021B (zh) 2012-04-21 2015-10-28 通化济达医药有限公司 含有锌结合基的吡啶并嘧啶类HDAC和mTOR抑制剂
WO2014146249A1 (en) * 2013-03-19 2014-09-25 Merck Sharp & Dohme Corp. Geminally substituted cyanoethylpyrazolo pyridones as janus kinase inhibitors
US9745297B2 (en) 2013-07-30 2017-08-29 Boehringer Ingelheim International Gmbh Compounds as modulators of RORC
RU2685234C1 (ru) 2013-12-09 2019-04-17 Юсб Байофарма Спрл Конденсированные бициклические гетероароматические производные в качестве модуляторов активности tnf
KR20150080966A (ko) 2014-01-02 2015-07-13 최돈수 유기 전기 발광 소자용 발광 재료, 이를 이용한 유기 전기 발광 소자 및 유기 전기 발광 소자용 재료
KR20160060572A (ko) 2014-11-19 2016-05-30 주식회사 엠비케이 유기 발광 화합물, 잉크 조성물, 유기 발광 소자 및 전자 기기
US10403826B2 (en) 2015-05-07 2019-09-03 Universal Display Corporation Organic electroluminescent materials and devices
EP3335254B1 (de) 2015-08-11 2020-04-08 Merck Patent GmbH Materialien für organische elektrolumineszenzvorrichtungen
WO2017031427A1 (en) 2015-08-19 2017-02-23 3-V Biosciences, Inc. COMPOUNDS AND METHODS FOR INHIBITING mTOR
KR102606277B1 (ko) 2016-04-06 2023-11-27 삼성디스플레이 주식회사 유기 발광 소자
US10573692B2 (en) 2016-04-06 2020-02-25 Samsung Display Co., Ltd. Organic light-emitting device having a sealing thin film encapsulation portion
WO2017181177A1 (en) 2016-04-15 2017-10-19 Epizyme, Inc. Amine-substituted aryl or heteroaryl compounds as ehmt1 and ehmt2 inhibitors
JP2019537557A (ja) 2016-10-04 2019-12-26 エナンタ ファーマシューティカルズ インコーポレイテッド Ｆｘｒアゴニストとしてのイソキサゾール類似体およびその使用方法
WO2018066812A1 (en) 2016-10-05 2018-04-12 Rohm And Haas Electronic Materials Korea Ltd. Organic electroluminescent compound and organic electroluminescent device comprising the same
WO2018108110A1 (zh) 2016-12-13 2018-06-21 广州华睿光电材料有限公司 金属有机配合物及其应用、混合物、有机电子器件
TW201843143A (zh) 2017-03-13 2018-12-16 德商麥克專利有限公司 含有芳基胺結構之化合物
WO2018169352A1 (en) 2017-03-16 2018-09-20 Rohm And Haas Electronic Materials Korea Ltd. Organic electroluminescent device
KR102335935B1 (ko) 2017-03-22 2021-12-06 덕산네오룩스 주식회사 유기전기소자용 화합물, 이를 이용한 유기전기소자 및 그 전자 장치
AU2018243749A1 (en) 2017-03-31 2019-11-21 Epizyme, Inc. Methods of using EHMT2 inhibitors
KR102389204B1 (ko) 2017-04-18 2022-04-21 덕산네오룩스 주식회사 유기전기 소자용 화합물, 이를 이용한 유기전기소자 및 그 전자 장치
AU2018254577A1 (en) 2017-04-21 2019-12-05 Epizyme, Inc. Combination therapies with EHMT2 inhibitors
WO2018204765A1 (en) 2017-05-05 2018-11-08 Pairnomix, Llc Methods of treating epilepsy and kcnq2 related conditions
US20200206196A1 (en) 2017-06-13 2020-07-02 Commonwealth Scientific And Industrial Research Organisation Antiviral Drugs
JPWO2019065516A1 (ja) 2017-09-26 2020-09-10 日本曹達株式会社 キノリン化合物および農園芸用殺菌剤
US20210260040A1 (en) 2017-10-18 2021-08-26 Epizyme, Inc. Methods of using ehmt2 inhibitors in treating or preventing blood disorders
EP3697420A4 (en) 2017-10-18 2021-11-24 Epizyme, Inc. METHODS OF USING EHMT2 INHIBITORS IN IMMUNOTHERAPIES
CN108484680B (zh) 2018-01-31 2020-12-11 马鞍山南京大学高新技术研究院 一类双硫代芳环/芳杂环磷酸化合物作为辅助配体的铱配合物
US11090304B2 (en) * 2018-05-04 2021-08-17 Amgen Inc. KRAS G12C inhibitors and methods of using the same
US20200075870A1 (en) 2018-08-22 2020-03-05 Universal Display Corporation Organic electroluminescent materials and devices
CN109265457A (zh) 2018-11-01 2019-01-25 中国药科大学 一种利用氧化芳构化构建吡啶并嘧啶二酮骨架的新方法
US20220204482A1 (en) 2019-05-10 2022-06-30 Antidote Ip Holdings, Llc Compounds and methods for treating cancer
CN110283171A (zh) 2019-07-17 2019-09-27 鼎泰(南京)临床医学研究有限公司 一类含有吡啶并嘧啶-4-胺类结构的化合物、药物组合物以及其应用
US11820783B2 (en) 2019-09-06 2023-11-21 Universal Display Corporation Organic electroluminescent materials and devices
TW202208355A (zh) 2020-05-04 2022-03-01 美商安進公司 作為骨髓細胞觸發受體2促效劑之雜環化合物及使用方法
CN111454265B (zh) 2020-05-07 2021-08-24 宁波卢米蓝新材料有限公司 一种稠杂环化合物及其制备方法和应用

Also Published As

Publication number Publication date
US11608344B2 (en) 2023-03-21
PE20230846A1 (es) 2023-05-23
US20230295170A1 (en) 2023-09-21
US20230002390A1 (en) 2023-01-05
US20230295169A1 (en) 2023-09-21
CL2022003047A1 (es) 2023-07-14
JP2023525035A (ja) 2023-06-14
CU20220064A7 (es) 2023-06-13
ECSP22089527A (es) 2023-02-28
CR20220560A (es) 2023-08-18
US11912711B2 (en) 2024-02-27
EP4146222A1 (en) 2023-03-15
CN115867284A (zh) 2023-03-28
MX2022013842A (es) 2023-02-22
TW202208355A (zh) 2022-03-01
CA3182105A1 (en) 2021-11-11
AU2021266805A1 (en) 2022-12-01
IL297833A (en) 2023-01-01
WO2021226629A1 (en) 2021-11-11
AR122010A1 (es) 2022-08-03
US11884675B2 (en) 2024-01-30
KR20230019822A (ko) 2023-02-09
CO2022015930A2 (es) 2023-01-26

Similar Documents

Publication Publication Date Title
BR112022022341A2 (pt) Compostos heterocíclicos como receptor desencadeador expresso em agonistas de células mieloides 2 e métodos de uso
BR112022022338A2 (pt) Compostos heterocíclicos como receptor desencadeador expresso em agonistas de células mieloides 2 e métodos de uso
UY38076A (es) Derivados de tetrahidroquinazolina útiles como agentes anticáncer
CO2021009240A2 (es) Compuestos moduladores de fxr (nr1h4)
SV2010003580A (es) Agonistas novedosos de los receptores de glucocorticoides
CO2018000344A2 (es) Derivados de piperidina 1,4-sustituidos
CU20110212A7 (es) Nuevos derivados de pirimidina y sus usos en el tratamiento del cáncer y otras enfermedades
NI201100050A (es) Derivados amida de heteroarilos su uso como activadores de glucoquinasa.
UY30292A1 (es) Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor b(beta)2 adrenérgico
BR112015005168A2 (pt) Derivados de c17-alcanodiila e alquenodiila de ácido oleanólico e métodos de uso dos mesmos
CU20110168A7 (es) Derivados de benzofuranilo
CR10875A (es) Derivados de ester y amida de indazolilo para el tratamiento de enfermedades mediadas por un receptor de glucocorticoides
BR112021026498A2 (pt) Composto, uso do composto e composição farmacêutica
BR122017015106B8 (pt) estrutura de cristal de formula 1b e composição farmacêutica
BRPI0815360B8 (pt) composto derivado de 4-pirimidinossulfamida, composição farmacêutica que o contem, uso e processo para a preparação do composto
CL2019003274A1 (es) Derivados de pirimidina como moduladores del receptor de pge2.
UY33655A (es) Co-cristales y sales de inhibidores de ccr30
CO2020005944A2 (es) Compuestos heterocíclicos sustituidos con amina como inhibidores de ehmt2, sales de los mismos, y métodos de síntesis de los mismos
UY37191A (es) Derivados de dibenzofurano para uso como inhibidores de bromodominio
UY32744A (es) Derivados de 2-carboxamida-7-piperazinil-benzofurano 774
BR112023023008A2 (pt) Compostos heterocíclicos como receptor desencadeador expresso em agonistas de células mieloides 2 e métodos de uso
AR069009A1 (es) Arilindenopirimidinas y su uso como antagonistas del receptor a₂a de adenosina
BR112022018996A2 (pt) 3-fenoxiazetidin-1-il-pirazinas substituídas apresentando atividade agonística do gpr52".
CO2021001174A2 (es) Inhibidores de ckd8/19
AR127622A1 (es) Compuestos heterocíclicos como agonistas del receptor activador expresado en células mieloides 2 y métodos de uso